Unknown

Dataset Information

0

Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.


ABSTRACT: Limited options are available for treating patients with advanced prostate cancer (PC). Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), an IL-10 family cytokine, exhibits pleiotropic anticancer activities without adversely affecting normal cells. We previously demonstrated that suppression of the prosurvival Bcl-2 family member, myeloid cell leukemia-1 (Mcl-1), is required for mda-7/IL-24-mediated apoptosis of prostate carcinomas. Here we demonstrate that pharmacological inhibition of Mcl-1 expression with the unique Apogossypol derivative BI-97C1, also called Sabutoclax, is sufficient to sensitize prostate tumors to mda-7/IL-24-induced apoptosis, whereas ABT-737, which lacks efficacy in inhibiting Mcl-1, does not sensitize mda-7/IL-24-mediated cytotoxicity. A combination regimen of tropism-modified adenovirus delivered mda-7/IL-24 (Ad.5/3-mda-7) and BI-97C1 enhances cytotoxicity in human PC cells, including those resistant to mda-7/IL-24 or BI-97C1 alone. The combination regimen causes autophagy that facilitates NOXA- and Bim-induced and Bak/Bax-mediated mitochondrial apoptosis. Treatment with Ad.5/3-mda-7 and BI-97C1 significantly inhibits the growth of human PC xenografts in nude mice and spontaneously induced PC in Hi-myc transgenic mice. Tumor growth inhibition correlated with increased TUNEL staining and decreased Ki-67 expression in both PC xenografts and prostates of Hi-myc mice. These findings demonstrate that pharmacological inhibition of Mcl-1 with the Apogossypol derivative, BI-97C1, sensitizes human PCs to mda-7/IL-24-mediated cytotoxicity, thus potentially augmenting the therapeutic benefit of this combinatorial approach toward PC.

SUBMITTER: Dash R 

PROVIDER: S-EPMC3102401 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.

Dash Rupesh R   Azab Belal B   Quinn Bridget A BA   Shen Xuening X   Wang Xiang-Yang XY   Das Swadesh K SK   Rahmani Mohamed M   Wei Jun J   Hedvat Michael M   Dent Paul P   Dmitriev Igor P IP   Curiel David T DT   Grant Steven S   Wu Bainan B   Stebbins John L JL   Pellecchia Maurizio M   Reed John C JC   Sarkar Devanand D   Fisher Paul B PB  

Proceedings of the National Academy of Sciences of the United States of America 20110509 21


Limited options are available for treating patients with advanced prostate cancer (PC). Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), an IL-10 family cytokine, exhibits pleiotropic anticancer activities without adversely affecting normal cells. We previously demonstrated that suppression of the prosurvival Bcl-2 family member, myeloid cell leukemia-1 (Mcl-1), is required for mda-7/IL-24-mediated apoptosis of prostate carcinomas. Here we demonstrate that pharmacological  ...[more]

Similar Datasets

| S-EPMC3171699 | biostudies-literature
| S-EPMC3228882 | biostudies-literature
| S-EPMC3113954 | biostudies-literature
| S-EPMC4090725 | biostudies-literature
| S-EPMC3647237 | biostudies-literature
| S-EPMC2880850 | biostudies-literature
| S-EPMC2739016 | biostudies-literature
| S-EPMC3915776 | biostudies-literature
| S-EPMC6431152 | biostudies-literature
| S-EPMC3388565 | biostudies-literature